American Association for Cancer Research
Browse
10780432ccr193154-sup-229665_2_supp_5959904_q2g58h.pdf (23.46 kB)

Supplementary Figure SF6 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial

Download (23.46 kB)
journal contribution
posted on 2023-03-31, 22:05 authored by Daniel Rodriguez Gutierrez, Chris Jones, Pascale Varlet, Alan Mackay, Daniel Warren, Monika Warmuth-Metz, Esther Sánchez Aliaga, Raphael Calmon, Darren R. Hargrave, Adela Cañete, Maura Massimino, Amedeo A. Azizi, Marie-Cécile Le Deley, Frank Saran, Raphael F. Rousseau, Gudrun Zahlmann, Josep Garcia, Gilles Vassal, Jacques Grill, Paul S. Morgan, Tim Jaspan

Significantly different radiological characteristics of H3 G34-mutant compared to other Cerebral wild-type cases

History

ARTICLE ABSTRACT

The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma (HGG). The work presented here aims to correlate imaging characteristics and outcome measures with pathologic and molecular data. Radiological, pathologic, and molecular data were correlated with trial clinical information to retrospectively re-evaluate event-free survival (EFS) and overall survival (OS). One-hundred thirteen patients were randomized to the RT/TMZ arm (n = 54) or the RT/TMZ+BEV (BEV arm; n = 59). The tumor arose in the cerebral hemispheres in 68 patients (Cerebral group) and a midline location in 45 cases (Midline group). Pathologic diagnosis was available in all cases and molecular data in 86 of 113. H3 K27M histone mutations were present in 23 of 32 Midline cases and H3 G34R/V mutations in 7 of 54 Cerebral cases. Total/near-total resection occurred in 44 of 68 (65%) Cerebral cases but in only 5 of 45 (11%) Midline cases (P < 0.05). Leptomeningeal metastases (27 cases, 13 with subependymal spread) at relapse were more frequent in Midline (17/45) than in Cerebral tumors (10/68, P < 0.05). Mean OS (14.1 months) and EFS (9.0 months) in Midline tumors were significantly lower than mean OS (20.7 months) and EFS (14.9 months) in Cerebral tumors (P < 0.05). Pseudoprogression occurred in 8 of 111 (6.2%) cases. This study has shown that the poor outcome of midline tumors (compared with cerebral) may be related to (1) lesser surgical resection, (2) H3 K27M histone mutations, and (3) higher leptomeningeal dissemination.

Usage metrics

    Clinical Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC